Cochrane Nigeria

Have you seen Cochrane's vision for a healthier future? 🌏 Cochrane's new scientific strategy takes on the most pressing global health challenges to create a healthier, more equitable world. Key focus areas include: 🔹 Maternal, newborn & child health 🔹 Multiple chronic conditions 🔹 Infectious diseases 🔹 Climate change & sustainability This strategy is underpinned by commitments to: ✨ Innovating research methods ✨ Promoting health equity ✨ Global collaboration ✨ Championing research integrity 🎤 Dr. Karla Soares-Weiser, Cochrane’s Editor-in-Chief, aptly stated: "In an era marked by unprecedented global health challenges, the need for reliable, high-quality health evidence has never been more critical." By addressing these urgent issues, Cochrane is paving the way for informed health decisions and better outcomes for all. If you haven’t already, check out Cochrane's scientific strategy and see how we are working to shape a healthier, more sustainable world! 👉 Learn more about the strategy here: https://lnkd.in/gQzN6JFN #HealthEquity #GlobalHealth #EvidenceBased #Sustainability #Cochrane

Advancing Care for Solid Organ Transplant Recipients: Preventing CMV Disease Cytomegalovirus (CMV) is a major concern for solid organ transplant recipients, often leading to severe illness or death within the first year post-transplant. A comprehensive review provides promising findings: Antiviral medications (e.g., ganciclovir, valaciclovir) reduce the risk of CMV disease and related deaths across kidney, heart, and liver transplant patients. Longer prophylaxis improves outcomes for kidney and lung transplant recipients. Low-dose valganciclovir is equally effective as standard doses in moderate-risk kidney transplant recipients. While antiviral therapy shows significant benefits, future studies should explore optimized regimens for seronegative donor-recipient groups and evolving immunosuppressive protocols. Read more: https://lnkd.in/dtkYnjfx Authors: Robin WM Vernooij, Mini Michael, Maleeka Ladhani, Angela C Webster, Giovanni FM Strippoli, Jonathan C Craig, Elisabeth M Hodson #TransplantCare #cmvprevention #AntiviralTherapy #OrganTransplant

Oxygen Therapy in Extremely Preterm Infants: Striking the Right Balance For preterm babies born before 28 weeks’ gestation, targeting the right oxygen levels can significantly impact outcomes. A comprehensive review of five trials involving 4965 infants assessed the benefits and risks of targeting lower (85%-89%) vs. higher (91%-95%) oxygen saturation levels. Key Findings: Higher oxygen targets reduced the risk of death and necrotizing enterocolitis. Low oxygen targets decreased the risk of retinopathy of prematurity requiring treatment. Both Findings have trade-offs that healthcare teams must weigh carefully. With high-quality evidence for most outcomes, this review empowers healthcare teams to make informed decisions for preterm infants’ care. Read more: https://lnkd.in/dgvtF9uD Authors: Lisa M Askie, Brian A Darlow, Peter G Davis, Neil Finer, Ben Stenson, Maximo Vento, Robin Whyte #neonatology #PretermInfants #OxygenSaturation #evidencebasedcare

What if healthcare decisions were backed by good, quality and reproducible evidence? Systematic reviews drive better patient outcomes and reduced healthcare costs. Here's how they shape healthcare policies and treatment decisions. #EvidenceBasedHealthcare #HealthcareInnovation

🌟 Celebrating Our Volunteers on #InternationalVolunteerDay! 🌟 At Cochrane, we are incredibly grateful for the time, energy and skills that our volunteers dedicate to advancing healthcare evidence. Your contributions make a real difference in developing, producing and sharing trusted information about what works in healthcare worldwide. As part of this year’s #InternationalVolunteerDay, we’re excited to share our new Cochrane Membership Badges, designed to recognise and celebrate the vital role our volunteers play. Check them out here: https://lnkd.in/ddVgsy9G. To every Cochrane volunteer, we extend our heartfelt thanks today and every day. Together, we’re making healthcare decisions better for everyone. #ThankYouVolunteers #IVD2024

Point‐of‐care tests for detecting high viral load in people living with HIV attending healthcare facilities As we reflect on World AIDS Day (December 1st), it's essential to explore advances in HIV care. A recent review highlights the potential of point-of-care (POC) tests in diagnosing high viral loads (≥ 1000 copies/mL) in people living with HIV (PLHIV). Why is this important? POC tests enable healthcare providers to quickly identify treatment failure, adjust antiretroviral therapy (ART), and prevent severe health outcomes. Key findings: 14 studies, 8659 participants. POC tests showed promise but were mostly conducted in nearby labs, not directly at the patient’s side. While highly accurate, some false positives (leading to unnecessary treatment) and false negatives (missing ART failure) remain a concern. Implications: For every 1000 PLHIV tested, these molecular POC tests could help guide treatment for many but might still miss some high-risk cases. Improvements in accessibility and accuracy are crucial. Let’s use this momentum from World AIDS Day to advocate for better diagnostic tools and equitable access to care for all PLHIV. Together, we can achieve better outcomes! Read More: https://lnkd.in/dVwUCnmF Authors: Eleanor A OchodoEaster Elizabeth OlwandaJonathan J DeeksSue Mallett #HIVcare #pointofcarediagnostics #HealthInnovation #WorldAIDSDay2024

Hello December! At CochraneNigeria, we believe that evidence-based healthcare is a team effort. We're committed to collaborating with healthcare professionals, researchers, and stakeholders to deliver high-quality systematic reviews and Evidence-based Research. Together, let's strive for better patient outcomes and improved healthcare decision-making! #EvidenceBasedHealthcare #Collaboration #SystematicReviews

Did you know that Respiratory Syncytial Virus (RSV) vaccination during pregnancy can cut infant hospitalizations caused by RSV by half? Recent studies reveal this game-changing impact for maternal and infant health. key findings: Significant reduction in RSV-related hospitalizations in newborns. No increase in birth defects or fetal growth restriction. Potential safety signal for preterm births requires further investigation. RSV (Respiratory Syncytial Virus) is a leading cause of severe respiratory illness in young infants. Vaccinating during pregnancy transfers vital antibodies to the fetus, providing early immunity during the most vulnerable months. This evidence is shaping how we prevent RSV in infants globally. Future research will delve into timing, geographic differences, and attitudes toward maternal vaccination. Read more: https://lnkd.in/daSSrptz #maternalhealth #rsvvaccination #infantcare #PreventiveMedicine #PublicHealth

Prematurity is a global health challenge, with over 13 million babies born too soon each year. It is also a leading cause of death among under-five children. To raise awareness and drive action, November 17th is designated as World Prematurity Day, and this year’s theme, “Access to Quality Care Everywhere,” focuses on ensuring quality care for Small and Sick Newborns (SSNBs), especially premature infants. The Nigerian Society of Neonatal Medicine (NISONM), in collaboration with the Pediatric Association of Nigeria (PAN), is taking the lead with impactful initiatives, including: 1. Advocacy for preemies and their families 2. Public health education campaigns on radio, TV, and social media 3. Nationwide training on Essential Newborn Care 1 (Helping Babies Breathe) for healthcare providers, accompanied by distribution of critical resuscitation tools and action plans. Together, these efforts aim to translate knowledge into practice and improve neonatal care and outcomes for vulnerable preemies across Nigeria. Let’s join hands to ensure that every preemie, everywhere, has access to quality care. Share, support, and advocate for change. #WorldPrematurityDay2024 #AccessToQualityCareEverywhere #PaediatricAssociationofNigeria #NISONM

Can Magnesium Sulphate Protect Babies Born Preterm? Research reveals that magnesium sulphate, when administered to women at risk of preterm birth, can reduce the occurrence of cerebral palsy and the combined outcome of death or cerebral palsy in children up to two years old. This is a significant development in neonatal care, with studies showing that magnesium sulphate may protect brain health for infants born before 34 weeks of pregnancy. Key findings: Magnesium sulphate significantly reduces the risk of cerebral palsy or death in children up to two years of age when given to women likely to deliver preterm. There is limited evidence to suggest any significant impact of magnesium sulphate on outcomes for children at early school age. Research will continue to explore its long-term effects and determine optimal delivery methods for diverse groups. Read more: https://lnkd.in/dXtkEYip Authors: Emily S Shepherd, Shona Goldsmith, Lex W Doyle, Philippa Middleton, Stéphane Marret, Dwight J Rouse, Peter Pryde, Hanne T Wolf, Caroline A Crowther #pretermbirth #maternalhealth #neonatalcare #MagnesiumSulphate #cerebralpalsy #healthcareresearch